Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Room 7137, Madison, Wisconsin 53705, United States.
Chem Rev. 2020 Apr 22;120(8):3787-3851. doi: 10.1021/acs.chemrev.9b00738. Epub 2020 Mar 23.
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as Zr-Df-pertuzumab and Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
免疫正电子发射断层扫描(immunoPET)是一种具有变革性的分子成像模式,结合了单克隆抗体(mAb)的卓越靶向特异性和 PET 技术的固有敏感性。已经开发了各种放射性核素和 mAb 来开发 immunoPET 探针,这是由于放射化学和缀合策略的发展和优化推动的。此外,还使用具有短循环时间(例如,纳米抗体)或增强结合亲和力(例如,双特异性抗体)的肿瘤靶向载体来设计新型 immunoPET 探针。因此,已经成功地将几种 immunoPET 探针(例如 Zr-Df-pertuzumab 和 Zr-atezolizumab)转化为临床应用。通过非侵入性和动态地揭示异质肿瘤抗原的表达,immunoPET 成像正在逐渐改变几种类型恶性肿瘤的治疗诊断格局。immunoPET 是用于成像特定肿瘤标志物、免疫细胞、免疫检查点和炎症过程的首选方法。此外,将 immunoPET 成像整合到抗体药物开发中具有重要意义,因为它提供了有关抗体靶向能力和分布特征的关键信息。本文介绍了最新的 immunoPET 成像策略及其在临床前和临床中的应用。我们还强调了当前的缀合策略,这些策略可以用于开发下一代 immunoPET 探针。最后,我们讨论了调整 immunoPET 成像策略的开发和转化的实际考虑因素。